News >

Experts Explain Impact of LATITUDE Abiraterone Data in Prostate Cancer

Angelica Welch and Danielle Bucco
Published: Wednesday, Aug 02, 2017

Jorge A. Garcia, MD

Jorge A. Garcia, MD
Adding abiraterone acetate (Zytiga) plus prednisone to androgen deprivation therapy (ADT) lowered the risk of death by 38% in men with newly diagnosed, high-risk, metastatic prostate cancer, according to findings from the phase III LATITUDE trial presented at the 2017 ASCO Annual Meeting.

discussed these practice-changing findings with Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, and Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre.

OncLive: Please provide the background for the LATITUDE trial.

Garcia: The standard of care for many years for men with prostate cancer has been castration, oftentimes orchiectomy or we do ADT therapy, which is basically hormonal suppression. That treatment protocol changed a couple years ago with the results of CHAARTED and also with STAMPEDE, where we demonstrated that adding docetaxel to ADT lead to survival improvement in men with castration-sensitive metastatic disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x